Evidence map›Paper›PMID 29262617›Full record

ArticleOncotarget2017

Microtubins: a novel class of small synthetic microtubule targeting drugs that inhibit cancer cell proliferation.

Silvia Senese, Yu-Chen Lo, Ankur A Gholkar, Chien-Ming Li, Yong Huang, Jack Mottahedeh, Harley I Kornblum, Robert Damoiseaux, Jorge Z Torres

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Silvia SeneseDepartment of Chemistry and Biochemistry, University of California, Los Angeles, CA 90095, USA.
Yu-Chen LoDepartment of Chemistry and Biochemistry, University of California, Los Angeles, CA 90095, USA.
Ankur A GholkarDepartment of Chemistry and Biochemistry, University of California, Los Angeles, CA 90095, USA.
Chien-Ming LiDrug Studies Unit, Department of Bioengineering & Therapeutic Sciences, University of California, San Francisco, CA 94143, USA.
Yong HuangDrug Studies Unit, Department of Bioengineering & Therapeutic Sciences, University of California, San Francisco, CA 94143, USA.
Jack MottahedehDepartment of Molecular and Medical Pharmacology, Los Angeles, CA 90095, USA.
Harley I KornblumDepartment of Molecular and Medical Pharmacology, Los Angeles, CA 90095, USA.
Robert DamoiseauxDepartment of Molecular and Medical Pharmacology, Los Angeles, CA 90095, USA.
Jorge Z TorresDepartment of Chemistry and Biochemistry, University of California, Los Angeles, CA 90095, USA.
University of California, Los Angeles · USLos Angeles Medical Center · USUniversity of California, San Francisco · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI David A. Nathanson · 2017 to 2026
$25.2M
Neural Progenitor Genes and Brain TumorsR01NS052563 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KORNBLUM, HARLEY IAN · 2006 to 2015
$2.4M
Neural Progenitor Genes and Brain TumorsR56NS052563 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KORNBLUM, HARLEY IAN · 2010 to 2010
$231k
NCI NIH HHS P30 CA016042NCI NIH HHS P50 CA211015NINDS NIH HHS R01 NS052563NINDS NIH HHS R56 NS052563
6 · The paper itself

Abstract

Microtubule targeting drugs like taxanes, vinca alkaloids, and epothilones are widely-used and effective chemotherapeutic agents that target the dynamic instability of microtubules and inhibit spindle functioning. However, these drugs have limitations associated with their production, solubility, efficacy and unwanted toxicities, thus driving the need to identify novel antimitotic drugs that can be used as anticancer agents. We have discovered and characterized the Microtubins (Microtubule inhibitors), a novel class of small synthetic compounds, which target tubulin to inhibit microtubule polymerization, arrest cancer cells predominantly in mitosis, activate the spindle assembly checkpoint and trigger an apoptotic cell death. Importantly, the Microtubins do not compete for the known vinca or colchicine binding sites. Additionally, through chemical synthesis and structure-activity relationship studies, we have determined that specific modifications to the Microtubin phenyl ring can activate or inhibit its bioactivity. Combined, these data define the Microtubins as a novel class of compounds that inhibit cancer cell proliferation by perturbing microtubule polymerization and they could be used to develop novel cancer therapeutics.

Indexed as

cancer cell proliferationcell cyclecell divisionmicrotubulestubulin-targeting agents

Identifiers

PMID29262617
PMCPMC5732783
OpenAlexW2766821727

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.